Eric von Hofe, PhD, president and chief operating officer of AffyImmune, discussed advantages of the Affinity tuning platform.
Eric von Hofe, PhD
Advertisement
President and Chief Operating Officer, AffyImmune
Articles by Eric von Hofe, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based Primarily on Phase 1/2 Data
2
FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More
3
